Thermal Energy International Inc. will announce its fiscal 2026 fourth quarter and full-year financial results before market open on September 22, 2026. The company will host a live webcast and conference call at 8:30 a.m. ET the same day, including a Q&A session for analysts and investors. Financial statements and management's discussion will be available on SEDAR+ and the company's website following the release. This update is important for investors tracking the company’s performance in energy efficiency and emissions reduction solutions globally.
Thermal Energy International's upcoming fiscal 2026 results provide context for energy sector activity. For readers following the energy sector, here is Pluang's market snapshot as of Sep 17, 2026 18:11 WIB: Among 30 priced US energy stocks, 21 rose and 8 fell. Devon Energy Corp (DVN) traded at USD 48.64 with a 1-day change of +0.41% and a typical hold time of 134 days, while Cenovus Energy Inc (CVE) was at USD 32.39, down 0.40%, with a much shorter hold time of 45 days and a high buy order activity of 95%. Kinder Morgan Inc (KMI) stood at USD 30.85, up 0.39%, with a hold time of 148 days and 69% buy orders on Pluang.
Vereigen Media's Verified Content Engagement (VCE) solution won Gold at the 2026 TITAN Business Awards for improving B2B lead quality through first-party data, human verification, and engagement validation. This approach helps marketing teams deliver...
UBS Group AG has officially notified that it holds 7,768,727 shares in Bang & Olufsen A/S, representing 5.27% of the company's total share capital and voting rights as of October 9, 2026. This disclosure is made in compliance with the Danish Capital ...
Norsk Hydro will publish its third-quarter 2026 financial results on October 23, 2026, at 07:00 CEST. The company's CEO and CFO will present the results via a live webcast at 08:30 CEST the same day, allowing investors to ask questions online. There ...
On October 14, 2026, Michael Brierley, a Non-Executive Director of Admiral Group plc, and his wife Rachel Brierley acquired shares of the company through a dividend reinvestment trading plan. The transactions involved purchasing ordinary shares at pr...
The FDA has approved Roche's Enspryng (satralizumab) as the first and only at-home subcutaneous treatment for adults with thyroid eye disease (TED). This approval follows positive results from Phase III SatraGO-2 trials showing significant reductions...
